X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq:XFOR) announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 3:45 p.m. ET. A live and archived webcast of the presentation will be available via the Investors section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – XFOR
On the day this news was published, XFOR gained 0.75%, reflecting a mild positive market reaction. This price movement added approximately $3M to the company's valuation, bringing the market cap to $392.37M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Positive | +4.3% | Q1 2026 results, EU XOLREMDI authorization, cash runway through 2028. |
| Apr 29 | EU approval news | Positive | -0.5% | European Commission marketing authorization for XOLREMDI in WHIM syndrome. |
| Apr 01 | Equity inducement grants | Neutral | -2.5% | Inducement option awards totaling 32,000 shares under 2019 plan. |
| Mar 17 | FY 2025 earnings | Positive | +18.8% | Q4 and 2025 results, 4WARD Phase 3 progress, strong cash position. |
| Mar 04 | Conference participation | Neutral | +5.1% | Management fireside chat at Leerink Global Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most prior news and earnings events saw price moves that aligned with the generally positive tone, with only one notable divergence after EU approval news.
Over the last few months, X4 reported multiple milestones, including EU marketing authorization for XOLREMDI and progress in the 4WARD Phase 3 trial. Earnings on Mar 17, 2026 and May 6, 2026 highlighted substantial cash balances of $253.0M and $233.7M, funding operations through 2028. The company also announced equity inducement grants and conference participation. Today’s Jefferies conference presentation fits into an ongoing pattern of active investor and corporate communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET.
A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com
Source: X4 Pharmaceuticals, Inc.
